Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping

ES Costa, CE Pedreira, S Barrena, Q Lecrevisse, J Flores, S Quijano, J Almeida, MD Garcia-Macias, S Bottcher, Jacques Dongen, A Orfao

Research output: Contribution to journalArticleAcademicpeer-review

112 Citations (Scopus)

Abstract

Immunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is becoming increasingly complex due to usage of progressively larger panels of reagents and a high number of World Health Organization (WHO) entities. Typically, data analysis is performed separately for each stained aliquot of a sample; subsequently, an expert interprets the overall immunophenotypic profile (IP) of neoplastic B-cells and assigns it to specific diagnostic categories. We constructed a principal component analysis (PCA)-based tool to guide immunophenotypic classification of B-CLPD. Three reference groups of immunophenotypic data files-FB-cell chronic lymphocytic leukemias (B-CLL; n = 10), mantle cell (MCL; n = 10) and follicular lymphomas (FL; n = 10)-were built. Subsequently, each of the 175 cases studied was evaluated and assigned to either one of the three reference groups or to none of them (other B-CLPD). Most cases (89%) were correctly assigned to their corresponding WHO diagnostic group with overall positive and negative predictive values of 89 and 96%, respectively. The efficiency of the PCA-based approach was particularly high among typical B-CLL, MCL and FL vs other B-CLPD cases. In summary, PCA-guided immunophenotypic classification of B-CLPD is a promising tool for standardized interpretation of tumor IP, their classification into well-defined entities and comprehensive evaluation of antibody panels. Leukemia (2010) 24, 1927-1933; doi:10.1038/leu.2010.160; published online 16 September 2010
Original languageUndefined/Unknown
Pages (from-to)1927-1933
Number of pages7
JournalLeukemia
Volume24
Issue number11
DOIs
Publication statusPublished - 2010

Research programs

  • EMC MM-02-72-03

Cite this